Helena Yu, MD
Memorial Sloan Kettering Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Helena Yu, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:07 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT07535437 · A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung CancerMemorial Sloan Kettering Cancer Center · recruiting · Non-Small Cell Lung Cancer · principal investigator
- Ph2NCT04965090 · A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC)Memorial Sloan Kettering Cancer Center · completed · Metastatic Non Small Cell Lung Cancer, Recurrent Non Small Cell Lung Cancer · principal investigator
- Ph2NCT04410796 · Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung CancersMemorial Sloan Kettering Cancer Center · recruiting · Metastatic Non-small Cell Lung Cancer · principal investigator
- Ph1NCT03810807 · Study of Dacomitinib and Osimertinib for Patients With Advanced EGFR Mutant Lung CancerMemorial Sloan Kettering Cancer Center · completed · Metastatic Non-small Cell Lung Cancer · principal investigator
- Ph1NCT03567642 · A Study of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung CancersMemorial Sloan Kettering Cancer Center · active not recruiting · Lung Cancer · principal investigator
- Ph1/Ph2NCT03076164 · A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to ErlotinibMemorial Sloan Kettering Cancer Center · completed · Lung Adenocarcinoma, Lung Cancer, Lung Cancer Metastatic · principal investigator
- Ph1/Ph2NCT02803203 · Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung CancersMemorial Sloan Kettering Cancer Center · completed · Non-small Cell Lung Cancer, EGFR-mutant Lung Cancers · principal investigator
- N/ANCT02450591 · Local Therapies for Oligometastatic Non-Small Cell Lung Cancer Harboring Sensitizing EGFR MutationsMemorial Sloan Kettering Cancer Center · completed · Oligometastatic Lung Adenocarcinoma · principal investigator
- N/ANCT02186236 · Detection of Oncogenic Tumor Mutations in the Urine and Blood of Lung and Colorectal Cancer PatientsMemorial Sloan Kettering Cancer Center · completed · Lung Cancer, Colorectal Cancer · principal investigator
- Ph1/Ph2NCT02155465 · Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to ErlotinibMemorial Sloan Kettering Cancer Center · completed · Lung Cancer · principal investigator
- Ph1NCT01967095 · Low Dose Daily Erlotinib in Combination With High Dose Twice Weekly Erlotinib in Patients With EGFR-Mutant Lung CancerMemorial Sloan Kettering Cancer Center · completed · EGFR-Mutant Lung Cancer · principal investigator
- N/ANCT00579683 · Registry for Patients With Acquired Resistance to Small Molecule Kinase Inhibitors in Non-Small-Cell Lung CancerMemorial Sloan Kettering Cancer Center · completed · Unresectable or Metastatic Non-small Cell Lung Cancer (NSCLC) · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:07 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in non-small cell lung cancer.